| Treatment . | Frequency . | Percent . | Cumulative frequency . | Cumulative percent . |
|---|---|---|---|---|
| None | 25 | 22.12 | 25 | 22.12 |
| Tafamidis 20 | 76 | 67.26 | 101 | 89.38 |
| Tafamidis 61 | 10 | 8.85 | 111 | 98.23 |
| Patisiran or placebo 50% | 2 | 1.76 | 113 | 100.00 |
| Treatment . | Frequency . | Percent . | Cumulative frequency . | Cumulative percent . |
|---|---|---|---|---|
| None | 25 | 22.12 | 25 | 22.12 |
| Tafamidis 20 | 76 | 67.26 | 101 | 89.38 |
| Tafamidis 61 | 10 | 8.85 | 111 | 98.23 |
| Patisiran or placebo 50% | 2 | 1.76 | 113 | 100.00 |
| Treatment . | Frequency . | Percent . | Cumulative frequency . | Cumulative percent . |
|---|---|---|---|---|
| None | 25 | 22.12 | 25 | 22.12 |
| Tafamidis 20 | 76 | 67.26 | 101 | 89.38 |
| Tafamidis 61 | 10 | 8.85 | 111 | 98.23 |
| Patisiran or placebo 50% | 2 | 1.76 | 113 | 100.00 |
| Treatment . | Frequency . | Percent . | Cumulative frequency . | Cumulative percent . |
|---|---|---|---|---|
| None | 25 | 22.12 | 25 | 22.12 |
| Tafamidis 20 | 76 | 67.26 | 101 | 89.38 |
| Tafamidis 61 | 10 | 8.85 | 111 | 98.23 |
| Patisiran or placebo 50% | 2 | 1.76 | 113 | 100.00 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
